Cargando…
Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct
Mutations in glucocerebrosidase cause the lysosomal storage disorder Gaucher’s disease and are the most common risk factor for Parkinson’s disease. Therapies to restore the enzyme’s function in the brain hold great promise for treating the neurological implications. Thus, we developed blood-brain ba...
Autores principales: | Gehrlein, Alexandra, Udayar, Vinod, Anastasi, Nadia, Morella, Martino L., Ruf, Iris, Brugger, Doris, von der Mark, Sophia, Thoma, Ralf, Rufer, Arne, Heer, Dominik, Pfahler, Nina, Jochner, Anton, Niewoehner, Jens, Wolf, Luise, Fueth, Matthias, Ebeling, Martin, Villaseñor, Roberto, Zhu, Yanping, Deen, Matthew C., Shan, Xiaoyang, Ehsaei, Zahra, Taylor, Verdon, Sidransky, Ellen, Vocadlo, David J., Freskgård, Per-Ola, Jagasia, Ravi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097658/ https://www.ncbi.nlm.nih.gov/pubmed/37045813 http://dx.doi.org/10.1038/s41467-023-37632-4 |
Ejemplares similares
-
Characterization of Novel Human β-glucocerebrosidase Antibodies for Parkinson Disease Research
por: Jong, Tiffany, et al.
Publicado: (2023) -
A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells
por: Deen, Matthew C., et al.
Publicado: (2022) -
Brain Shuttle Neprilysin reduces central Amyloid-β levels
por: Campos, Christopher R., et al.
Publicado: (2020) -
Glucocerebrosidase and its relevance to Parkinson disease
por: Do, Jenny, et al.
Publicado: (2019) -
Potent and Selective BACE-1 Peptide Inhibitors Lower Brain Aβ Levels Mediated by Brain Shuttle Transport
por: Ruderisch, Nadine, et al.
Publicado: (2017)